207 related articles for article (PubMed ID: 24834836)
1. Intracellular role of exchangeable apolipoproteins in energy homeostasis, obesity and non-alcoholic fatty liver disease.
Wu CL; Zhao SP; Yu BL
Biol Rev Camb Philos Soc; 2015 May; 90(2):367-76. PubMed ID: 24834836
[TBL] [Abstract][Full Text] [Related]
2. The exchangeable apolipoproteins in lipid metabolism and obesity.
Su X; Peng D
Clin Chim Acta; 2020 Apr; 503():128-135. PubMed ID: 31981585
[TBL] [Abstract][Full Text] [Related]
3. The role of apolipoprotein A5 in obesity and the metabolic syndrome.
Zheng XY; Zhao SP; Yan H
Biol Rev Camb Philos Soc; 2013 May; 88(2):490-8. PubMed ID: 23279260
[TBL] [Abstract][Full Text] [Related]
4. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients.
Wree A; Schlattjan M; Bechmann LP; Claudel T; Sowa JP; Stojakovic T; Scharnagl H; Köfeler H; Baba HA; Gerken G; Feldstein AE; Trauner M; Canbay A
Metabolism; 2014 Dec; 63(12):1542-52. PubMed ID: 25267016
[TBL] [Abstract][Full Text] [Related]
5. Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.
Feng Q; Baker SS; Liu W; Arbizu RA; Aljomah G; Khatib M; Nugent CA; Baker RD; Forte TM; Hu Y; Zhu L
Pathology; 2015 Jun; 47(4):341-8. PubMed ID: 25938357
[TBL] [Abstract][Full Text] [Related]
6. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
[TBL] [Abstract][Full Text] [Related]
7. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.
Su X; Kong Y; Peng DQ
Lipids Health Dis; 2018 Jul; 17(1):174. PubMed ID: 30053818
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines.
Panera N; Della Corte C; Crudele A; Stronati L; Nobili V; Alisi A
Expert Rev Gastroenterol Hepatol; 2016; 10(3):393-403. PubMed ID: 26654761
[TBL] [Abstract][Full Text] [Related]
9. Peroxisomes compensate hepatic lipid overflow in mice with fatty liver.
Knebel B; Hartwig S; Haas J; Lehr S; Goeddeke S; Susanto F; Bohne L; Jacob S; Koellmer C; Nitzgen U; Müller-Wieland D; Kotzka J
Biochim Biophys Acta; 2015 Jul; 1851(7):965-76. PubMed ID: 25790917
[TBL] [Abstract][Full Text] [Related]
10. Role of gut microbiota: obesity and NAFLD.
Gangarapu V; Yıldız K; Ince AT; Baysal B
Turk J Gastroenterol; 2014 Apr; 25(2):133-40. PubMed ID: 25003671
[TBL] [Abstract][Full Text] [Related]
11. Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.
Silvestri C; Paris D; Martella A; Melck D; Guadagnino I; Cawthorne M; Motta A; Di Marzo V
J Hepatol; 2015 Jun; 62(6):1382-90. PubMed ID: 25595882
[TBL] [Abstract][Full Text] [Related]
12. Adipocyte-hepatocyte crosstalk in cellular models of obesity: Role of soluble factors.
Baldini F; Diab F; Serale N; Zeaiter L; Portincasa P; Diaspro A; Vergani L
Life Sci; 2023 Mar; 317():121464. PubMed ID: 36731646
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific DNA methylation profiles regulate liver-specific expression of the APOA1/C3/A4/A5 cluster and can be manipulated with demethylating agents on intestinal cells.
Guardiola M; Oliva I; Guillaumet A; Martín-Trujillo Á; Rosales R; Vallvé JC; Sabench F; Del Castillo D; Zaina S; Monk D; Ribalta J
Atherosclerosis; 2014 Dec; 237(2):528-35. PubMed ID: 25463085
[TBL] [Abstract][Full Text] [Related]
14. Autophagy: Emerging roles in lipid homeostasis and metabolic control.
Christian P; Sacco J; Adeli K
Biochim Biophys Acta; 2013 Apr; 1831(4):819-24. PubMed ID: 23274236
[TBL] [Abstract][Full Text] [Related]
15. Hepatosteatosis and estrogen increase apolipoprotein O production in the chicken.
Schmidinger B; Weijler AM; Schneider WJ; Hermann M
Biochimie; 2016 Aug; 127():37-43. PubMed ID: 27126072
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease.
Ishtiaq SM; Rashid H; Hussain Z; Arshad MI; Khan JA
Rev Endocr Metab Disord; 2019 Sep; 20(3):253-261. PubMed ID: 31656991
[TBL] [Abstract][Full Text] [Related]
17. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
Jakel H; Nowak M; Helleboid-Chapman A; Fruchart-Najib J; Fruchart JC
Ann Med; 2006; 38(1):2-10. PubMed ID: 16448983
[TBL] [Abstract][Full Text] [Related]
18. Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism.
Rodríguez A; Ezquerro S; Méndez-Giménez L; Becerril S; Frühbeck G
Am J Physiol Endocrinol Metab; 2015 Oct; 309(8):E691-714. PubMed ID: 26330344
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion.
Sundaram M; Yao Z
Arterioscler Thromb Vasc Biol; 2012 May; 32(5):1073-8. PubMed ID: 22517365
[TBL] [Abstract][Full Text] [Related]
20. Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction.
Lopategi A; López-Vicario C; Alcaraz-Quiles J; García-Alonso V; Rius B; Titos E; Clària J
Mol Cell Endocrinol; 2016 Jan; 419():44-59. PubMed ID: 26433072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
